TriviumVet's felycin -CA1 has been granted conditional approval by the U.S.
Food and Drug Administration.
The drug is indicated for managing ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy.
It is the first and only medication shown to reduce the ventricularHypertrophy that is the principal feature of subclinical HCM.
Read the Entire Article